image credit: Vecteezy

AstraZeneca’s Fasenra receives FDA approval for paediatric patients with severe asthma

April 15, 2024


The approval was based on evidence from the open-label phase 3 TATE trial in addition to well-controlled trials in adult and adolescent populations.

Asthma is one of the most common chronic childhood diseases and causes coughing, wheezing and difficulty breathing.

SEA is a serious form of asthma that occurs when white blood cells known as eosinophils become overreactive and cause inflammation in the lungs and airways.

Read More on PMLiVE